ANRO Stock Overview
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Alto Neuroscience, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.10 |
| 52 Week High | US$24.00 |
| 52 Week Low | US$12.78 |
| Beta | 0 |
| 1 Month Change | 10.58% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -22.22% |
Recent News & Updates
Shareholder Returns
| ANRO | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 13.4% | 3.0% | -0.7% |
| 1Y | n/a | 12.5% | 22.8% |
Return vs Industry: Insufficient data to determine how ANRO performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ANRO performed against the US Market.
Price Volatility
| ANRO volatility | |
|---|---|
| ANRO Average Weekly Movement | 12.8% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ANRO's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine ANRO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 61 | Amit Etkin | www.altoneuroscience.com |
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD.
Alto Neuroscience, Inc. Fundamentals Summary
| ANRO fundamental statistics | |
|---|---|
| Market cap | US$416.64m |
| Earnings (TTM) | -US$36.30m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-11.9x
P/E RatioIs ANRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANRO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$36.31m |
| Earnings | -US$36.30m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.35 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 13.9% |
How did ANRO perform over the long term?
See historical performance and comparison